Autoimmune neurologic syndromes can be paraneoplastic (associated with malignancies and/or onconeural antibodies), or non-paraneoplastic. Their clinical presentation is often similar. As prognosis is related to malignancy treatment, better biomarkers are needed to identify patients with malignancy. We investigated cerebrospinal fluid (CSF) markers of neuronal (neurofilament light chain, NFL and total tau protein, T-tau) and glial (glial fibrillary acidic protein) damage. CSF-NFL and T-tau were increased in both paraneoplastic and non-paraneoplastic autoimmune syndromes. Patients with manifest malignancies were older, had less epilepsy, more focal central and peripheral neurological signs and symptoms, and worse long-term outcome, than those without malignancy. CSF-NFL-levels predicted long-term outcome but were not diagnostic for malignancy, after age adjustment.
Introduction
Autoimmune neurological syndromes may be paraneoplastic [related to systemic malignancies and henceforward called paraneoplastic neurological syndromes (PaNS)] or non-paraneoplastic (non-PaNS), not related to malignancy. In PaNS a systemic malignancy sometimes expressing onconeuronal antigens triggers autoimmune processes which are responsible for the clinical symptoms (Dalmau and Rosenfeld, 2008; Graus et al., 2004) . The clinical presentation of autoimmune neurologic syndromes is variable and not specific enough for identifying patients with malignancies. It comprises central nervous manifestations, including autoimmune encephalitis, and peripheral neurological syndromes. Detecting a malignancy is imperative for improving the long-term prognosis but may be exceedingly difficult, involving a large number of malignancy investigations which, when negative, need to be repeated over several years (Darnell and Posner, 2003; Graus and Dalmau, 2007; Gromadzka et al., 2013; Titulaer et al., 2011) . Other available biomarkers such as cerebrospinal fluid (CSF) analysis, brain magnetic resonance imaging (MRI), and assessment of antibodies directed against neuronal surface and intracellular antigens, offer only limited additional help, as they often cannot differentiate patients with malignancies from those without (Psimaras et al., 2010; Graus et al., 2016; Dalmau et al., 2011) . Increased CSF levels of neuronal damage markers [neurofilament light chain (NFL) and total tau (T-tau) protein] but not of glial cell damage [glial fibrillary acidic protein (GFAP)] were found in autoimmune encephalitis. However, they were not studied separately in patients with underlying malignancies and those without (Constantinescu et al., 2016) and, to the best of our knowledge, they have never been investigated in PaNS. There is a need for better and clinically accessible biomarkers to rapidly identify patients with an underlying malignancy.
The aim of this study is to investigate patients with paraneoplastic and non-paraneoplastic autoimmune neurological syndromes and
